Ivantis to Pay $60M in Patent Litigation Settlement with Glaukos
“Glaukos NYSE, GKOS announced today that it entered into a settlement with Ivantis to terminate a three-year-old patent infringement lawsuit. San Clemente, California-based Glaukos’ patent infringement lawsuit, initiated on April 14, 2018, in the U.S. District Court for the Central District of California,” reports Sean Whooley in Drug Delivery.
“Under the settlement agreement, Ivantis will pay Glaukos $60 million, with $30 million to be paid by Dec. 31, 2021. The remainder must be paid by Dec. 31, 2022, with Ivantis also to pay Glaukos a 10% ongoing royalty through April 26, 2025, based on the Hydrus Microstent’s U.S. sales and any international sales supplied outside of the U.S.”
